SI2344677T1 - Postopki in sestavki za diagnosticiranje in zdravljenje multipli sklerozi sekundarne avtoimune bolezni - Google Patents

Postopki in sestavki za diagnosticiranje in zdravljenje multipli sklerozi sekundarne avtoimune bolezni

Info

Publication number
SI2344677T1
SI2344677T1 SI200931691T SI200931691T SI2344677T1 SI 2344677 T1 SI2344677 T1 SI 2344677T1 SI 200931691 T SI200931691 T SI 200931691T SI 200931691 T SI200931691 T SI 200931691T SI 2344677 T1 SI2344677 T1 SI 2344677T1
Authority
SI
Slovenia
Prior art keywords
diagnosis
compositions
treatment
methods
multiple sclerosis
Prior art date
Application number
SI200931691T
Other languages
English (en)
Inventor
Alasdair J. Coles
Joanne L. Jones
Alastair Compston
Original Assignee
Cambridge Enterprise Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Limited filed Critical Cambridge Enterprise Limited
Publication of SI2344677T1 publication Critical patent/SI2344677T1/sl

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034Isolating an individual clone by screening libraries
    • C12N15/1075Isolating an individual clone by screening libraries by coupling phenotype to genotype, not provided for in other groups of this subclass
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6827Hybridisation assays for detection of mutation or polymorphism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854Immunoglobulins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/172Haplotypes
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders
    • G01N2800/285Demyelinating diseases; Multipel sclerosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
SI200931691T 2008-10-08 2009-10-08 Postopki in sestavki za diagnosticiranje in zdravljenje multipli sklerozi sekundarne avtoimune bolezni SI2344677T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19565808P 2008-10-08 2008-10-08
US19718708P 2008-10-24 2008-10-24
US19863108P 2008-11-07 2008-11-07
EP09804308.6A EP2344677B1 (en) 2008-10-08 2009-10-08 Methods and compositions for diagnosis and treatment of autoimmune disease secondary to multiple sclerosis
PCT/IB2009/007327 WO2010041149A2 (en) 2008-10-08 2009-10-08 Methods and compositions for diagnosis and treatment

Publications (1)

Publication Number Publication Date
SI2344677T1 true SI2344677T1 (sl) 2017-10-30

Family

ID=42061141

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931691T SI2344677T1 (sl) 2008-10-08 2009-10-08 Postopki in sestavki za diagnosticiranje in zdravljenje multipli sklerozi sekundarne avtoimune bolezni

Country Status (22)

Country Link
US (4) US20110229470A1 (sl)
EP (2) EP3241910B1 (sl)
JP (2) JP5856481B2 (sl)
KR (2) KR101825457B1 (sl)
CN (1) CN102245783B (sl)
AU (1) AU2009302117B2 (sl)
BR (1) BRPI0920546B1 (sl)
CA (1) CA2740077A1 (sl)
CY (1) CY1119513T1 (sl)
DK (1) DK2344677T3 (sl)
ES (2) ES2784830T3 (sl)
HK (1) HK1246364A1 (sl)
HR (1) HRP20171023T1 (sl)
HU (1) HUE035208T2 (sl)
IL (1) IL212069A (sl)
LT (1) LT2344677T (sl)
MX (1) MX336835B (sl)
PL (2) PL3241910T3 (sl)
PT (2) PT3241910T (sl)
RU (1) RU2563521C2 (sl)
SI (1) SI2344677T1 (sl)
WO (1) WO2010041149A2 (sl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2835819A1 (en) 2011-05-16 2012-11-22 Genzyme Corporation Induction of immune tolerance using methotrexate
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
MA37681B2 (fr) * 2012-05-25 2020-07-29 Cellectis Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie
CN102786595B (zh) * 2012-08-03 2014-04-23 无锡傲锐东源生物科技有限公司 抗cd5蛋白单克隆抗体及其用途
KR20230164204A (ko) 2016-03-10 2023-12-01 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
EP3487875A4 (en) * 2016-07-19 2020-02-12 Arete Discoveries, Inc. BIOMARKERS FOR THE DETECTION AND TREATMENT OF DISORDERS ASSOCIATED WITH THE ACTIVITY OF MASTOCYTES
JP6827113B2 (ja) 2017-01-21 2021-02-10 広州白雲山漢方現代薬業有限公司Guangzhou Hanfang Pharmaceutical Co.,Ltd. シェーグレン症候群の治療におけるペオニフロリン−6’−o−ベンゼンスルホン酸の使用
CA3076373A1 (en) 2017-09-20 2019-03-28 Io Therapeutics, Inc. Treatment of disease with esters of selective rxr agonists
US11672092B2 (en) * 2019-11-06 2023-06-06 Steiner Enterprises Modular electrical distribution system for vehicles
EP4001919A1 (en) * 2020-11-13 2022-05-25 Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal Predictive biomarkers of autoimmunity in patients treated with alemtuzumab
EP4337958A1 (en) * 2021-05-13 2024-03-20 Genzyme Corporation Novel predictive biomarkers for secondary autoimmunity after lymphocyte depleting therapy
US11896558B2 (en) 2021-12-07 2024-02-13 Io Therapeutics, Inc. Use of an RXR agonist and taxanes in treating Her2+ cancers

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6351720B1 (en) 1997-10-24 2002-02-26 Mitsubishi Heavy Industries, Ltd. Trolley camera position detecting apparatus
US6045501A (en) * 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
US6315720B1 (en) * 2000-10-23 2001-11-13 Celgene Corporation Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug
JP2005501545A (ja) 2001-09-04 2005-01-20 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド カスパーゼ結合タンパク質、その調製物および使用
AU2002336676A1 (en) * 2001-11-05 2003-05-19 Zymogenetics, Inc Il-21 antagonists
WO2003050257A2 (en) 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
PT1531850E (pt) 2002-06-07 2012-05-07 Zymogenetics Inc Utilização de il-21 e anticorpo monoclonal para tratar cancros sólidos
CN1849131A (zh) * 2003-03-21 2006-10-18 Wyeth公司 用白介素-21/白介素-21受体的激动剂治疗免疫性疾病
EP1670501A2 (en) * 2003-09-25 2006-06-21 ZymoGenetics, Inc. Methods of treating autoimmune diseases using il-21
EP1773394A2 (en) 2004-08-05 2007-04-18 Wyeth a Corporation of the State of Delaware Antagonizing interleukin-21 receptor activity
EP2567973B1 (en) * 2005-11-28 2014-05-14 Zymogenetics, Inc. IL-21 antagonists

Also Published As

Publication number Publication date
PL3241910T3 (pl) 2020-10-19
IL212069A (en) 2016-04-21
ES2632213T3 (es) 2017-09-11
EP2344677A2 (en) 2011-07-20
EP3241910B1 (en) 2020-01-08
MX336835B (es) 2016-02-03
JP5856481B2 (ja) 2016-02-09
MX2011003730A (es) 2011-07-28
HK1246364A1 (zh) 2018-09-07
CN102245783A (zh) 2011-11-16
KR20110094276A (ko) 2011-08-23
WO2010041149A3 (en) 2010-09-30
JP2014195462A (ja) 2014-10-16
US20200191799A1 (en) 2020-06-18
RU2011118477A (ru) 2012-11-20
BRPI0920546A2 (pt) 2020-06-02
RU2563521C2 (ru) 2015-09-20
JP2012504954A (ja) 2012-03-01
US11243211B2 (en) 2022-02-08
PL2344677T3 (pl) 2017-11-30
US10598670B2 (en) 2020-03-24
HUE035208T2 (hu) 2018-05-02
DK2344677T3 (en) 2017-07-24
US20160356788A1 (en) 2016-12-08
HRP20171023T1 (hr) 2017-10-06
US20110229470A1 (en) 2011-09-22
CA2740077A1 (en) 2010-04-15
LT2344677T (lt) 2017-09-25
EP2344677B1 (en) 2017-04-05
KR101825457B1 (ko) 2018-02-05
PT3241910T (pt) 2020-04-07
AU2009302117B2 (en) 2016-07-28
EP3241910A1 (en) 2017-11-08
CY1119513T1 (el) 2018-03-07
KR20160140984A (ko) 2016-12-07
AU2009302117A1 (en) 2010-04-15
ES2784830T3 (es) 2020-10-01
US20220349899A1 (en) 2022-11-03
IL212069A0 (en) 2011-06-30
WO2010041149A2 (en) 2010-04-15
PT2344677T (pt) 2017-07-13
BRPI0920546B1 (pt) 2021-08-10
CN102245783B (zh) 2015-12-16
KR101682730B1 (ko) 2016-12-05

Similar Documents

Publication Publication Date Title
HK1246364A1 (zh) 多發性硬化症繼發的自身免疫疾病的診斷和治療的方法和組合物
IL267014A (en) Preparations and methods for the treatment of autoimmune diseases and other diseases
HK1249446A1 (zh) 用於治療乳糜瀉的組合物和方法
IL225519A0 (en) Effective preparations and methods for the treatment and diagnosis of inflammatory bowel disease
IL258794B (en) Methods and preparations for the diagnosis and treatment of cancer
EP2382228A4 (en) COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY AND AUTOIMMUNE DISEASES
EP2219669A4 (en) COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES
IL214255A0 (en) Methods and compositions for diagnosis and treatment of cancer
EP2411006A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF RENAL DISORDERS
IL215856A0 (en) Compositions and methods for treatment of cardiovascular disease
EP2633054A4 (en) NEW COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE AND ALLERGIC DISEASES
EP2437780A4 (en) THERAPEUTIC COMPOSITIONS AND METHOD FOR THE PREVENTION OF AUTOIMMUNE DISEASES
HK1167101A1 (en) Compositions and methods for treatment of multiple sclerosis
EP2405747A4 (en) COMPOSITIONS AND METHODS FOR TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES
EP2491143A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND TREATMENT OF GENETIC RETINOPATHY
EP2262509A4 (en) GALLIUM COMPOUNDS AND METHOD OF USE FOR THE TREATMENT OF INFLAMMATORY ENDURANCE
EP2147013A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS AND TREATMENT OF DEPRESSION AND FEARING
HU0900195D0 (en) Diagnosis and treatment of gluten-induced autoimmune diseases
HU0900199D0 (en) Diagnosis of gluten-induced autoimmune diseases